L04AX02 · Antineoplastic and immunomodulating agents
Thalidomide BMS (previously Thalidomide Celgene)
Indications
Thalidomide BMS in combination with melphalan and prednisone as first line treatment of patients with untreated multiple myeloma, aged >/= 65 years or ineligible for high dose chemotherapy. Thalidomide BMS is prescribed and dispensed according to the Thalidomide Celgene Pregnancy Prevention Programme (see section 4.4).
Composition
- Active substance
- thalidomide
Official product information
The European public assessment report holds the summary of product characteristics and the package leaflet in every EU language.
Prognia shows this product information for reference and learning. It is not treatment advice and can lag behind the official text. Always check the current product information and local protocols before prescribing.
At a glance
- Medicine
- Thalidomide BMS (previously Thalidomide Celgene)
- Active substance
- thalidomide
- ATC code
- L04AX02
- Therapeutic area
- Multiple Myeloma